Home ›
HER2 Negative Breast Cancer Trials ›
NCT06383767
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer.
Trial Details
NCT ID NCT06383767
Phase PHASE3
Sponsor Qilu Pharmaceutical Co., Ltd.
Status RECRUITING
Cancer Type HER2 Negative Breast Cancer
Interventions ESG401 Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)
Locations (sample) Beijing, Beijing Municipality, China|39.9075,116.39723
Key Eligibility Criteria
Individuals able to understand and give written informed consent. Males or females aged ≥ 18 years ; Histologically and/or cytologically confirmed HR+/HER2- breast cancer who had failed at least one line of systemic chemotherapy in metastatic setti… Patients who are eligible for a chemotherapy regimen in the control group;
For full eligibility, visit ClinicalTrials.gov .